ECSP099723A - Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer - Google Patents

Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer

Info

Publication number
ECSP099723A
ECSP099723A EC2009009723A ECSP099723A ECSP099723A EC SP099723 A ECSP099723 A EC SP099723A EC 2009009723 A EC2009009723 A EC 2009009723A EC SP099723 A ECSP099723 A EC SP099723A EC SP099723 A ECSP099723 A EC SP099723A
Authority
EC
Ecuador
Prior art keywords
quinaxoline
pi3k
alfa
cancer treatment
inhibiting compounds
Prior art date
Application number
EC2009009723A
Other languages
English (en)
Inventor
Peter Lamb
David Matthews
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of ECSP099723A publication Critical patent/ECSP099723A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona métodos de tratar cáncer por la administración de un compuesto de Fórmula I, opcionalmente en forma de sus sales farmacéuticamente aceptable, sus solvatos y/o hidratos, en combinación con otros tratamientos de cáncer. I
EC2009009723A 2007-04-11 2009-11-09 Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer ECSP099723A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92316407P 2007-04-11 2007-04-11
PCT/US2008/004570 WO2008127594A2 (en) 2007-04-11 2008-04-08 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ECSP099723A true ECSP099723A (es) 2010-03-31

Family

ID=39864581

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009723A ECSP099723A (es) 2007-04-11 2009-11-09 Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer

Country Status (34)

Country Link
US (1) US8481001B2 (es)
EP (1) EP2139483B9 (es)
JP (2) JP5726515B2 (es)
KR (1) KR101586774B1 (es)
CN (2) CN101959516B (es)
AU (1) AU2008239668B2 (es)
BR (1) BRPI0810208A2 (es)
CA (1) CA2684056A1 (es)
CO (1) CO6140024A2 (es)
CR (1) CR11099A (es)
CY (1) CY1114608T1 (es)
DK (1) DK2139483T3 (es)
EA (1) EA019064B1 (es)
EC (1) ECSP099723A (es)
ES (1) ES2438998T3 (es)
GT (1) GT200900263A (es)
HK (1) HK1140141A1 (es)
HR (1) HRP20131081T1 (es)
IL (1) IL201211A (es)
MA (1) MA31335B1 (es)
ME (1) ME00937B (es)
MX (1) MX2009010929A (es)
MY (1) MY150797A (es)
NI (1) NI200900184A (es)
NZ (1) NZ580009A (es)
PL (1) PL2139483T3 (es)
PT (1) PT2139483E (es)
RS (1) RS53020B (es)
SI (1) SI2139483T1 (es)
SV (1) SV2009003390A (es)
TN (1) TN2009000399A1 (es)
UA (1) UA98141C2 (es)
WO (1) WO2008127594A2 (es)
ZA (1) ZA200906765B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101492795B1 (ko) * 2005-10-07 2015-02-13 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
ES2513165T3 (es) * 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
RS52939B (en) * 2007-04-10 2014-02-28 Exelixis Inc. PROCEDURES FOR THE CANCER TREATMENT USING PI3K ALPHA PIRIDOPYRIMIDINONE INHIBITORS
PL2374802T3 (pl) 2008-11-10 2014-09-30 Kyowa Hakko Kirin Co Ltd Inhibitor wytwarzania kinureniny
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011100319A1 (en) 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
WO2012006552A1 (en) 2010-07-09 2012-01-12 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
AR082985A1 (es) 2010-09-14 2013-01-23 Exelixis Inc INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
DE102010048800A1 (de) * 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
KR20130141528A (ko) 2010-10-20 2013-12-26 메르크 세로노 에스에이 제네바 치환 ｎ-(3-아미노-퀴녹살린-2-일)-술폰아미드 및 이들의 중간체인 ｎ-(3-클로로-퀴녹살린-2-일)술폰아미드의 제조 방법
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2013040337A1 (en) * 2011-09-14 2013-03-21 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
AU2012318580A1 (en) * 2011-10-04 2014-05-22 Gilead Calistoga Llc Novel quinoxaline inhibitors of PI3K
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
WO2013063000A1 (en) * 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
JP6013498B2 (ja) * 2011-11-01 2016-10-25 エクセリクシス， インク． リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
WO2013067306A1 (en) * 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
WO2013101964A1 (en) * 2011-12-27 2013-07-04 Kadmon Corporation, Llc Methods for treatment of breast cancer nonresponsive to trastuzumab
JP6077642B2 (ja) 2012-04-10 2017-02-08 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、その調製法、中間体、組成物、及び使用
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
WO2015043398A1 (zh) 2013-09-30 2015-04-02 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6139789B2 (ja) 2013-10-16 2017-05-31 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合複素環化合物、その調製方法、医薬組成物及びその使用
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
US9950194B2 (en) 2014-09-09 2018-04-24 Mevion Medical Systems, Inc. Patient positioning system
WO2019119206A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc ANTICANCER THERAPY
NZ565749A (en) * 2005-08-26 2010-12-24 Serono Lab Pyrazine derivatives and use as PI3K inhibitors
KR101492795B1 (ko) 2005-10-07 2015-02-13 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
ES2513165T3 (es) 2005-10-07 2014-10-24 Exelixis, Inc. Derivados de N-(3-amino-quinoxalin-2-il)-sulfonamida y su uso como inhibidores de la fosfatidilinositol-3-quinasa
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
ZA200904857B (en) * 2007-02-22 2010-09-29 Merck Serono Sa Quinoxaline compounds and use thereof
RS52939B (en) 2007-04-10 2014-02-28 Exelixis Inc. PROCEDURES FOR THE CANCER TREATMENT USING PI3K ALPHA PIRIDOPYRIMIDINONE INHIBITORS
JP4623164B2 (ja) * 2008-08-21 2011-02-02 セイコーエプソン株式会社 プロジェクタ

Also Published As

Publication number Publication date
SV2009003390A (es) 2010-05-21
NZ580009A (en) 2012-06-29
HRP20131081T1 (hr) 2013-12-20
PT2139483E (pt) 2013-12-27
CO6140024A2 (es) 2010-03-19
IL201211A (en) 2015-09-24
AU2008239668B2 (en) 2013-11-07
WO2008127594A2 (en) 2008-10-23
CR11099A (es) 2010-01-19
CN101959516A (zh) 2011-01-26
NI200900184A (es) 2011-09-08
RS53020B (en) 2014-04-30
JP5726515B2 (ja) 2015-06-03
EP2139483A2 (en) 2010-01-06
ZA200906765B (en) 2010-05-26
EA019064B1 (ru) 2013-12-30
US20110123434A1 (en) 2011-05-26
BRPI0810208A2 (pt) 2014-10-21
SI2139483T1 (sl) 2013-11-29
ES2438998T3 (es) 2014-01-21
PL2139483T3 (pl) 2014-02-28
WO2008127594A3 (en) 2009-04-30
CY1114608T1 (el) 2016-10-05
JP2010523669A (ja) 2010-07-15
HK1140141A1 (en) 2010-10-08
TN2009000399A1 (fr) 2010-12-31
KR101586774B1 (ko) 2016-01-19
JP2014074031A (ja) 2014-04-24
AU2008239668A1 (en) 2008-10-23
EA200970935A1 (ru) 2010-04-30
MY150797A (en) 2014-02-28
CN103202842A (zh) 2013-07-17
US8481001B2 (en) 2013-07-09
CA2684056A1 (en) 2008-10-23
MA31335B1 (fr) 2010-04-01
ME00937B (me) 2012-06-20
UA98141C2 (ru) 2012-04-25
KR20100019436A (ko) 2010-02-18
CN101959516B (zh) 2013-05-08
DK2139483T3 (da) 2014-01-13
MX2009010929A (es) 2010-01-20
EP2139483B1 (en) 2013-09-18
GT200900263A (es) 2014-01-15
IL201211A0 (en) 2010-05-31
EP2139483B9 (en) 2014-05-21

Similar Documents

Publication Publication Date Title
ECSP099723A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer
ECSP099724A (es) Uso de inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cáncer
DOP2009000159A (es) Inhibidores de la poli(adp-ribosa) polimerasa
CY1120619T1 (el) Χημικες οντοτητες
TR201900306T4 (tr) Mek inhibitörlerini kullanma yöntemleri.
ECSP067080A (es) DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA
PA8740901A1 (es) Compuestos organicos
ECSP067068A (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA PARA LA INHIBICIÓN DE b-SECRETASA
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR077629A1 (es) Mimetico de smac
EA201490194A1 (ru) Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
CL2008002369A1 (es) Compuestos derivados de piridin-3-il-oxipiridin-2-il-amino, inhibidores de alk5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del cancer.
SV2009003389A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
NI201800065A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento de cáncer
ES2530755T3 (es) Terapia de combinación para el tratamiento del cáncer
CL2009001112A1 (es) Compuestos derivados de cinolin-3-carboxamida, inhibidores de la quinasa csf-1r; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
GT200600268A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento del cáncer
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer